# Metabolic & Weight Research research peptides — Booking Peptides > Booking Peptides is a literature digest on four metabolic research peptides — semaglutide, tirzepatide, retatrutide, and tesamorelin. Peer-reviewed citations. No products, no medical advice. A reading desk for the published science on four peptides studied for weight management and metabolic regulation — what was tested, in which species, and how strong the evidence really is. ## The short version This desk covers four peptides that researchers study for weight management and metabolic health. A *peptide* is a short chain of amino acids — the same building blocks as proteins, just much smaller — engineered to interact with specific receptors in the body. Three of the four here target incretin receptors, the signaling pathway that tells the pancreas to respond to glucose and tells the brain to stop eating. The fourth, tesamorelin, takes a different route: it primes the pituitary gland to release more growth hormone, which then drives fat out of visceral depots. Two of these are FDA-approved medicines. One is an investigational compound still in Phase 3. One carries an approval for a single narrowly defined indication. This desk tells you which is which, what the studies actually found, and — equally important — what they did not. No doses, no medical advice, no products. ## What this desk covers Four compounds, one metabolic theme. They differ in mechanism, approval status, and depth of evidence: - [**Semaglutide**](/semaglutide) is the lead. A long-acting GLP-1 receptor agonist, FDA-approved for type 2 diabetes, chronic weight management, and cardiovascular risk reduction. It has the broadest human evidence base on this desk — multiple large randomized controlled trials across multiple outcomes [1][2][3][4]. - [**Tirzepatide**](/tirzepatide) adds a second receptor to the picture. By agonizing both GIP and GLP-1 receptors simultaneously, it produced greater weight loss than semaglutide in a head-to-head trial and is FDA-approved for type 2 diabetes and obesity [1][10][11]. - [**Retatrutide**](/retatrutide) adds a third. Its glucagon receptor arm raises energy expenditure alongside the appetite suppression shared with the GLP-1 class. Still investigational — not approved anywhere — but Phase 2 data showed approximately 24% weight loss at 48 weeks [15]. - [**Tesamorelin**](/tesamorelin) is the outlier. A GHRH analogue, not an incretin, it stimulates pulsatile growth-hormone release from the pituitary, which preferentially mobilizes visceral adipose tissue. Approved for HIV-associated lipodystrophy only [18]. [Compare these peptides](/compare) on mechanism, approval status, and evidence quality side by side. ## Weight-management research peptides, explained The frame for this desk is the one the literature itself uses: *weight management as a metabolic problem*. Obesity and its complications — type 2 diabetes, cardiovascular disease, metabolic liver disease — are not treated identically by these compounds, but they share the same upstream intervention point: energy homeostasis. Incretin-based agents (semaglutide, tirzepatide, retatrutide) reduce caloric intake primarily through central nervous system mechanisms. GLP-1 receptors in the hypothalamus and brainstem process satiety signals; agonizing them quiets appetite and modifies food preference [6]. Tirzepatide's GIP receptor arm and retatrutide's glucagon receptor arm layer additional metabolic effects on top. Tesamorelin approaches the same metabolic territory differently. Growth-hormone deficiency promotes visceral fat accumulation; tesamorelin corrects that deficit in a specific population and the fat follows [17][19]. All four are studied for what happens to body composition. None is a substitute for clinical evaluation. This desk reports the evidence; it does not recommend. ## What are research peptides? Proteins are long folded chains of amino acids — enzymes, hormones, structural scaffolding. Peptides are shorter chains made of the same building blocks. Because they are small and specific, they can act as keys that fit particular receptor locks, switching cell signaling on or off. The term *research peptide* usually means a peptide studied in a laboratory or clinical-trial context but not approved as a medicine for general use. This desk includes compounds at several stages: - Fully approved medicines (semaglutide, tirzepatide, tesamorelin for its specific indication) — the evidence here comes from their regulatory review package and peer-reviewed trials. - An investigational compound (retatrutide) — studied under clinical-trial conditions, not yet approved. When this desk reports a number — a percentage of weight lost, a hazard ratio — it reports it as the study did, with species and trial conditions. No figure here is a recommendation, and no dose appears anywhere on this site. --- A literature digest — what the studies found, in the species studied, stated plainly and stopped.